The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 3 rounds in the feed.
Venture capitalbaincapitallifesciences.comRounds from 2025-01-09 to 2025-10-14
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Kailera Kailera is a late clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies to provide options for people living with obesity | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $600M | 2025-10-14 | [ PART ] |
No sector on record.
Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. |
| $200M |
| 2025-02-12 |
| [ PART ] |
Timberlyne Therapeutics Timberlyne Therapeutics develops biopharmaceutical therapies for autoimmune diseases. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $180M | 2025-01-09 | [ LEAD ] |